FDA Decision Spurs Surge In uniQure (QURE) Stock Value
A significant regulatory event caused shares of UniQure N.V. (NASDAQ: QURE) to spike up 39.04% to $13.06. The U.S. Food and Drug Administration (FDA) has designated QURE’s investigational gene therapy, AMT-130, as a Breakthrough Therapy for the treatment of Huntington’s disease, a rare, inherited neurodegenerative disease for which there are currently no disease-modifying treatments. Regulatory …
FDA Decision Spurs Surge In uniQure (QURE) Stock Value Read More »
